Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Targeting MDM4/MDM2 binding interface for reactivation of p53 in cancer therapy

ABSTRACT: The aim of this experiment has been to investigate the transcriptional profile of HCT116 cells treated with Peptide-3 (Pep3) compared to untreated (NT), treated with solvent (DMSO) or with a mutated peptide (Pep3M) cells. Peptide-3 is a dodecapeptide able to interact with MDM2 at the levels of the interaction region of the MDM4 and MDM2 proteins, thereby interfering with the coopeartivy function of the proteins in the regulation of p53. This peptide is indeed able to specifically activate p53 and to cause apoptotis in different cancer cell lines and tumor growth inhibition in xenograft models. Three different experimental conditions have been analysed compared to untreated cells at time 0 (NT cells, the starting point of the treatment): cells treated with DMSO solvent (DMSO); treated with peptide-3 (Pep3) and with control peptide (Pep3M). The analysis has been performed at 24 and 48 hours after treatment. In addition, untreated cells after 24 hours of growth have been analysed as further control. All analyses have been performed in triplicates.

ORGANISM(S): Homo sapiens

SUBMITTER: Ivan Arisi 

PROVIDER: E-GEOD-62855 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Restoration of wild-type p53 tumor suppressor function has emerged as an attractive anticancer strategy. Therapeutics targeting the two p53-negative regulators, MDM2 and MDM4, have been developed, but most agents selectively target the ability of only one of these molecules to interact with p53, leaving the other free to operate. Therefore, we developed a method that targets the activity of MDM2 and MDM4 simultaneously based on recent studies indicating that formation of MDM2/MDM4 heterodimer co  ...[more]

Similar Datasets

Transcriptomics Targeting MDM4/MDM2 binding interface for reactivation of p53 in cancer therapy
2017-04-18 | GSE62855 | GEO
Transcriptomics Expression changes following combined treatment with RG7388 + GSK2830371
2016-01-20 | E-GEOD-75197 | biostudies-arrayexpress
Transcriptomics Lamin A/C is required for SHSY5Y neuroblastoma cell differentiation and its expression is linked to a less malignant phenotype.
2013-07-11 | E-GEOD-30677 | biostudies-arrayexpress
Transcriptomics EBIO does not induce cardiomyogenesis in human pluripotent stem cells but modulates cardiac subtype enrichment by lineage-selective survival
2017-01-04 | E-MTAB-5192 | biostudies-arrayexpress
Transcriptomics Mdm2 enhances stemness-promoting chromatin modifications through the Polycomb Repressor Complex 2 in a p53-Independent Manner [HCT116 microarray]
2015-12-31 | E-GEOD-73294 | biostudies-arrayexpress
Transcriptomics Mdm2 enhances stemness-promoting chromatin modifications through the Polycomb Repressor Complex 2 in a p53-Independent Manner [hMSC microarray]
2015-12-31 | E-GEOD-73601 | biostudies-arrayexpress
Transcriptomics Expression data from Saccharomyces cerevisiae treated with Small Molecule Enhancers of Rapamycin (SMERs)
2010-07-29 | E-GEOD-22269 | biostudies-arrayexpress
Transcriptomics Transcription profiling of human bronchial epithelial cells to low doses of cigarette smoke condensate - chronic exposure
2009-08-09 | E-GEOD-14383 | biostudies-arrayexpress
Genomics 0bd5ff11-79c5-4173-9e24-79de02714d26 - samples
| EGAD00001008723 | EGA
Transcriptomics RNA sequencing data of 2102EP, VM-CUB-1, Caki-1 and DU-145 cells treated with epigenetic agent LAK31 and DMSO as solvent control
2022-09-01 | GSE190022 | GEO